Fatty liver disease is one of the most common liver conditions in the world — and most people who have it don't know it. New research shows that GLP-1 medications like Wegovy, Ozempic, and Mounjaro don't just help with weight loss: they can directly treat fatty liver disease and prevent it from progressing into something far more serious.

In this article, we explain what fatty liver disease is, why it matters, and what the latest clinical trials show about GLP-1 medications and liver health.

What is fatty liver disease?

Fatty liver disease — now officially called MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) — is a condition where fat builds up inside liver cells. It was previously known as NAFLD (Non-Alcoholic Fatty Liver Disease). It has nothing to do with alcohol; the cause is typically obesity, type 2 diabetes, elevated cholesterol, or metabolic syndrome.

Fatty liver disease affects an estimated 25–30% of the Western population. Most people have no symptoms and discover it by chance during a blood test or scan.

MASLD vs MASH — what's the difference?

Fatty liver disease exists in two stages:

An estimated 20% of people with MASLD develop MASH, and of those, a significant proportion risk developing severe fibrosis. This makes early treatment of MASH important.

How do GLP-1 medications affect the liver?

GLP-1 receptors aren't only found in the pancreas and brain — they also exist in liver cells. When semaglutide or tirzepatide activates these receptors, several things happen at once:

Crucially, a large part of these effects occur beyond weight loss — the medication appears to act on the liver directly.

SYNERGY-NASH: tirzepatide and MASH

In 2024, the New England Journal of Medicine published the results of the SYNERGY-NASH trial — a phase 2 study testing tirzepatide (Mounjaro) in adults with biopsy-confirmed MASH and moderate to severe fibrosis (stage F2–F3).

The results were striking. After 52 weeks, MASH resolution was achieved by:

In addition, approximately 51% of participants in the highest dose group achieved at least one stage of fibrosis improvement. These are remarkable numbers compared to most other available treatments.

ESSENCE: semaglutide and MASH

Semaglutide (the active ingredient in Wegovy and Ozempic) was also studied in the large phase 3 ESSENCE trial. The study followed patients with MASH and fibrosis (stage F2–F3) over 72 weeks using weekly injections of semaglutide 2.4 mg.

For the first time in a phase 3 trial, semaglutide achieved a significant improvement in fibrosis — without worsening MASH. This breakthrough led the FDA to approve semaglutide for MASH with fibrosis in August 2025.

Tirzepatide has likewise received FDA approval for MASH based on the SYNERGY-NASH results, making it the second approved medication — after resmetirom (Rezdiffra) — for this condition.

Who benefits most?

Those most likely to benefit from GLP-1 treatment for fatty liver include people with:

If your doctor has told you your liver enzymes are elevated, it's worth asking whether GLP-1 medication might be relevant for you.

What GLP-1 medication cannot do

It's important to have realistic expectations. GLP-1 medication is not a guarantee against developing cirrhosis or liver cancer. Studies show that treatment can reverse and slow the disease for many people — but not everyone responds, and the effect depends on disease stage, lifestyle, and other treatments.

Alcohol significantly worsens fatty liver and should be minimised during treatment. Diet, exercise, and weight loss still play a central role.

What does this mean for your treatment?

Many people on Wegovy, Ozempic, or Mounjaro will find that liver fat decreases within the first few months — even before significant weight loss occurs. If you've been diagnosed with fatty liver disease, GLP-1 medication can therefore offer a double benefit: you lose weight and your liver improves.

Talk to your doctor about whether your treatment is optimally structured for liver health — and use tools like ClickDose to ensure you're injecting exactly the dose you've been prescribed.

Sources